Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron and TTNS Sequencing in OAB
NCT05188742Phase 4Unknown
- Sponsor
- Taipei Veterans General Hospital
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mirabegron in overactive bladder syndrome (OAB) (2 arms), sponsored by Taipei Veterans General Hospital. Primary endpoint: Overactive Bladder Symptom Score at 20 weeks. Status: unknown.
02
Drugs
mirabegron
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT05188742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188742.